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least important outcomes for antithrombotic therapy. These results might be 
informative for making treatment decisions.  
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OBJECTIVES: Symptoms of peripheral arterial disease (PAD) are frequently 
associated with impaired health-related quality-of-life (HRQOL), which, in turn, 
impacts overall life satisfaction. However, there are few reports of patient 
expectations related to PAD interventions. The purpose of this analysis was to 
evaluate treatment-related changes in HRQOL in the ORION study. METHODS: 
ORION enrolled 125 patients, at 28 US centers, who had been diagnosed with 
chronic, symptomatic iliac disease. Patients received ≤2 nitinol stents in the 
common and/or external iliac artery. The Walking Impairment Questionnaire 
(WIQ), a validated PAD-specific quality-of-life instrument, was completed by 
each patient to assess his or her walking distance, walking speed, and stair-
climbing ability. RESULTS: Significant improvements (p<.0001) in all 3 domain 
scores of the WIQ were reported at 12 months postintervention. The walking 
distance mean score increased from 14.56±19.36 at baseline to 55.88±38.02 at 12 
months. Walking speed and stair-climbing mean scores increased from 
18.38±19.18 and 26.14±26.91, respectively, at baseline to 47.96±31.80 and 
57.72±37.17 at 12 months. Prior to intervention, 20.2% of patients were able to 
walk no more than 50 feet and 21.0% could walk at least 1500 feet. Improvement 
in maximum walking distance was observed; at 12 months, only 5.5% of patients 
could walk no more than 50 feet, while 63.3% could walk at least 1500 feet. 
Postintervention, there was an approximately 5-fold increase in patients who 
could run/jog one city block at 12 months (34.9%), compared to baseline (7.3%) 
and an approximately 2-fold increase in those who could climb at least 3 flights 
of stairs at 12 months (62.4%), compared to baseline (32.3%). CONCLUSIONS: 
Significant improvements in HRQOL, related to walking and stair climbing 
ability, were observed after nitinol stent placement. Future studies will target 
whether pretreatment HRQOL patient education affects patient perception and 
satisfaction related to the procedure and provider.  
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OBJECTIVES: To evaluate the characteristics of existing patient-reported 
outcome (PRO) instruments assessing atrial fibrillation (AF)-specific health-
related quality of life (HRQOL) or symptoms, focusing on Food and Drug 
Administration (FDA) PRO guidance. METHODS: This review was conducted in 
two phases. In phase 1, multiple sources (PubMed, Embase, Patient-Reported 
Outcome and Quality of Life Instruments Database [PROQOLID], and 
ClinicalTrials.org) were reviewed to identify instruments. In phase 2, data related 
to the development and measurement properties (internal consistency and test-
retest reliability, convergent and divergent construct validity, known-groups 
validity, and responsiveness) of these instruments were compared. RESULTS: 
The literature search identified 625 studies. Six AF-specific measures were 
identified: four HRQOL instruments (Atrial Fibrillation Effect on Quality-of-Life 
[AFEQT], Atrial Fibrillation Quality of Life [AF-QoL], AF6 [a six-item AF 
questionnaire], Questionnaire for Quality of Life in AF [QLAF]) and two symptom 
assessments (Symptom Checklist—Frequency and Severity [SCL], University of 
Toronto Atrial Fibrillation Severity Scale [AFSS]). The AFEQT extensively involved 
AF patients in its development, establishing content validity. The AFEQT 
demonstrated robust measurement properties including internal consistency 
Cronbach’s alphas of 0.88-0.95 for domains, test-retest intraclass correlation 
coefficients of 0.7-0.8 for three of four domains and overall score, evidence of 
construct and known-groups validity, and responsiveness to treatment-related 
changes in a longitudinal study. The SCL and AFSS have demonstrated 
responsiveness in randomized controlled trial (RCT) settings but neither involved 
AF patients in the development process, and both have limited published 
psychometric validation data. CONCLUSIONS: No existing PRO measure appears 
likely to support an FDA PRO label claim in AF. The AFEQT is the strongest 
instrument for measuring AF-related HRQOL; additional studies are needed to 
assess responsiveness in RCT settings. The SCL and AFSS have significant 
limitations related to development and validation. Qualitative research with AF 
patients may provide support for the content validity of the symptom measures.  
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OBJECTIVES: The health related quality of life (HRQoL) among hypertensive 
patients is influenced by a number of factors. However, there is paucity of 
information on the determinants of HRQoL among hypertensive patients 
particularly from developing countries such as Pakistan. This study therefore 
aims to describe the predictors and correlates of HRQoL in a hypertensive 
population of Pakistan. METHODS: A questionnaire based, cross sectional study 
was conducted among 385 hypertensive patients visiting two public hospitals in 
the city of Quetta, Pakistan. Demographic and disease related data was obtained 
from the patients and their hospital records. The generic EQ-5D questionnaire 
was used to measure HRQoL while Drug Attitude Inventory and Hypertension 
Fact Questionnaire were used to measure medication adherence and 
hypertension related knowledge respectively. Scale scores were compared with 
Mann-Whitney and Kruskal-Wallis test. Spearman's rho correlation was used to 
envisage the correlates of HRQoL. Standard multiple regression analysis was 
performed to identify predictors of HRQoL. RESULTS: Patients in the current 
study reported poor HRQoL with mean score of 0.46±0.28. In terms of practical 
implementation, age (β=0.298, p<0.001), educational level (β=0.493, p=0.025) and 
knowledge score (β=0.351, p=0.024) reached level of significance in the 
multivariate analysis. The multiple regression analysis also found that variables 
like gender, occupation, income, locality, duration of disease and medication 
adherence were not significantly associated with HRQoL. CONCLUSIONS: The 
results of the present study provide an evidence for a model that correlates with 
patients’ socio-demographic information and HRQoL. The findings after 
implication in clinical practice can prove useful in guiding patients receiving 
treatment for HTN. It will also help the physicians to maintain and adjust 
treatment behaviours with drug or non drug related interventions.  
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OBJECTIVES: Although hypercholesterolemia (high levels of cholesterol in the 
blood) itself is asymptomatic, longstanding elevation of serum cholesterol can 
lead to increase the risk of cardiovascular disease, particularly coronary heart 
disease. In Russia, there are no solid estimates of the magnitude of this 
condition. This study is aimed to assess co-morbidity, quality of life (QoL), work 
productivity loss, activity impairment, and medical resource utilization in 
Russian urban adults with hypercholesterolemia. METHODS: Patients’ self-
reported data were collected from 2011 National Health and Wellness Survey 
(NHWS). Survey sample represented major urban areas in Russia. QoL was 
measured by the physical component summary (PCS) and mental component 
summary (MCS) scores of the SF-12v2 . Work productivity loss and activity 
impairment were measured by the validated Work Productivity and Activity 
Impairment (WPAI) questionnaire. Medical resource utilization was measured by 
health care provider visits, emergency room visits, and hospitalizations in the 
past 6 months. RESULTS: Of the 10,039 adult respondents, 802 (7.98%) were 
experiencing hypercholesterolemia, of which 89% self-reported physician 
diagnosis, and only 60% were currently using some sort of medication. Average 
age of patients diagnosed with high cholesterol was 53.2 years. Compared to 
those not experiencing hypercholesterolemia, the diagnosed group reported 
more comorbidities (headache 66%, hypertension 54%, sleep difficulties 54%, 
insomnia 44%, pain 41%, heartburn 40%), lower mean PCS (40.7 vs. 47.1), and 
similar MCS (41.8 vs. 43.8). More patients visited health care providers (88% vs. 
70%) and a higher percentage were hospitalized (14% vs. 9%) over the past 6 
months. Furthermore, hypercholesterolemia patients reported 34.2% impairment 
in daily activities compared to 25.0% in the not experiencing 
hypercholesterolemia group. All mentioned differences were statistically 
significant (p<0.05). CONCLUSIONS: From Russian NHWS results, patients 
experiencing hypercholesterolemia suffer from lower QOL, work productivity 
loss, and more comorbidities. Findings indicate there is still an unmet medical 
need in Russian hypercholesterolemia patients.  
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OBJECTIVES: To evaluate demographic, diagnostic, and treatment characteristics 
of patients with concomitant hypertension and dyslipidemia, stratified by body 
mass index (BMI) and the attainment of blood pressure (BP) and lipid targets in 
obese versus non-obese patients. METHODS: This retrospective study utilized 
data from 2004 to 2011 from the GE Centricity Electronic Medical Records 
database of a primary care physician group in Southwestern Pennsylvania. 
Patients having ‘active’ status (with one or more visit(s) to the physician), ≥18 
years of age, and having concomitant hypertension and dyslipidemia (identified 
based on diagnosis, medication, and BP/lipid measurements) were included. 
Patients were classified into three cohorts based on their BMI: normal-weight 
(≤24.9 kg/m2), overweight (25.0-29.9 kg/m2), and obese (≥30.0 kg/m2). Goal 
attainment for BP and lipid levels were assessed based on JNC 7 and NCEP ATP III 
guidelines, respectively. Univariate and multivariate analyses were conducted to 
compare BP and lipid goal attainment in obese versus non-obese. RESULTS: A 
total of 9,086 patients with concomitant hypertension and dyslipidemia were 
identified and categorized as normal weight (13.8%), overweight (33.7%) and 
obese (52.5%). Patients who were obese were younger (<65 years); more likely to 
have diabetes (P<0.001); had higher baseline BP, triglyceride levels and lower 
HDL-C (P<0.05); and more likely to be prescribed both antihypertensives and 
antilipemic agents (P<0.001). In multivariate analyses, obese patients were 
significantly more likely to fail to attain BP (OR=1.562, P<0.001) and dual BP and 
LDL-C (OR=1.193, P=0.023) goals as well as optimal levels of triglycerides 
(OR=1.864, P<0.001) and HDL-C (OR=1.933, P=0.009). CONCLUSIONS: Obesity 
